CoronaryAtlas logo
CoronaryAtlas
SM (d18:1/22:0)
Pathway / Myocardial injury (shared endpoint)

SM (d18:1/22:0)

lipid

Decreased sphingomyelin content post-MI reflects myocardial lipid catabolism and severity of cardiomyocyte injury and dysfunction.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencemedium
RationaleDecreased sphingomyelin predicts post-MI mortality; myocardial lipid remodeling and injury severity marker.
Also acts inSystemic / off-pathway
Druggability
Not assessed (no mapped human gene target).

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma (EDTA to limit oxidation)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
LC-MS/MS lipidomics (targeted or shotgun)
Reagent / substrate
Deuterated lipid-class internal standards; MS/MS transitions
Platform
LC-MS/MS
Turnaround · availability
Research · Research-only

Literature evidence(1)